Real World Evidence of the Efficacy and Safety of FOQUEST

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

257 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-19

Study Completion Date

2021-07-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a four-month, phase IV, open-label study of ADHD symptomatology and functional outcomes in pediatric (6 to 17 years old) and adult (≥18 years or older) patients with ADHD treated with FOQUEST or VYVANSE.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the Effect Foquest® on Sleep in Children Aged 6-12 With ADHD

NCT04741516

Attention Deficit Hyperactivity Disorder

UNKNOWN PHASE4

Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD

NCT00141063

ADHD

COMPLETED PHASE3

Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD

NCT00141050

ADHD

COMPLETED PHASE3

Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

NCT00776009

Attention-Deficit/Hyperactivity Disorder (ADHD)

COMPLETED PHASE4

Safety, Tolerability and PK Study of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD.

NCT03546400

Attention Deficit Hyperactivity Disorder (ADHD)

WITHDRAWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After giving written, informed consent or assent (for patients \<18 years old), patients will be screened to ascertain their suitability for the study according to the patient selection criteria (Section 4). Based on clinician assessment, patients will be assigned to receive either FOQUEST or VYVANSE. Patients will be titrated to their optimal dose of ADHD medication based on Investigator judgement. At monthly visits, patients will have their ADHD symptomatology evaluated by the Investigator (ADHD-Rating Scale-DSM 5 Version \[ADHD-RS-5\]) and will complete questionnaires on functional outcomes (Weiss Functional Impairment Ratings Scale - Parent \[WFIRS-P\] or Weiss Functional Impairment Ratings Scale - Self \[WFIRS-Self\]), morning and evening behaviours (Daily Parent Rating of Evening and Morning Behaviours - Revised \[DPREMB-R\] or Adult ADHD Quality of Life Rating Scale - Revised \[AAQoL-R\]) and Patient Sleep \& Satisfaction survey (PSS). Safety will be evaluated through non-directed spontaneous adverse event (AE) reporting. Patients will be monitored for signs of suicide-related behavior, as per standard of care. A post-study safety follow-up phone call (conducted between 7 and 14 days post-last visit) will assess patients for any adverse events that occur following their last dose of medication received as part of the study. Following the last dose of study medication, the patient's continuing, post-study ADHD treatment will be based on Investigator discretion and standard of care.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Attention Deficit-Hyperactivity Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FOQUEST adults

adult (≥18 years or older) patients with ADHD receiving FOQUEST (controlled-release methylphenidate 25 mg, 35 mg, 45 mg, 55 mg, 70 mg, 85 mg, or 100 mg/day)

Group Type EXPERIMENTAL

Methylphenidate Hydrochloride

Intervention Type DRUG

CR Methylphenidate Hydrochloride given once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, 85 mg or 100 mg)

VYVANSE adults

adult (≥18 years or older) patients with ADHD receiving VYVANSE (lisdexamfetamine 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg/day)

Group Type ACTIVE_COMPARATOR

Lisdexamfetamine Dimesylate

Intervention Type DRUG

Lisdexamfetamine Dimesylate given once daily (10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg)

FOQUEST pediatric

pediatric (6 to 17 years old) patients with ADHD receiving FOQUEST (controlled-release methylphenidate 25 mg, 35 mg, 45 mg, 55 mg or 70 mg/day)

Group Type EXPERIMENTAL

Methylphenidate Hydrochloride

Intervention Type DRUG

CR Methylphenidate Hydrochloride given once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, 85 mg or 100 mg)

VYVANSE pediatric

pediatric (6 to 17 years old) patients with ADHD receiving VYVANSE (lisdexamfetamine 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg/day)

Group Type ACTIVE_COMPARATOR

Lisdexamfetamine Dimesylate

Intervention Type DRUG

Lisdexamfetamine Dimesylate given once daily (10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Methylphenidate Hydrochloride

CR Methylphenidate Hydrochloride given once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, 85 mg or 100 mg)

Intervention Type DRUG

Lisdexamfetamine Dimesylate

Lisdexamfetamine Dimesylate given once daily (10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

FOQUEST ADHANSIA XR VYVANSE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Pediatric: Male or non-pregnant, non-nursing female patients the age of 6 to less than 18. Adults: Male or non-pregnant, non-nursing female patients the age of 18 or older.
2. Diagnosed with ADHD (inattentive, hyperactive or combined-type) who are deemed eligible to receive treatment with FOQUEST or VYVANSE, as per the respective Product Monograph.
3. Mentally and physically competent to provide informed consent, or assent and able and willing to comply with the study protocol, including the study duration.

Exclusion Criteria

Potential patients who meet any of the contraindications or warnings detailed in the respective Canadian Product Monographs are excluded from participation in the study:

1. Having a true allergy to methylphenidate or amphetamines or sympathomimetic amines, history of serious adverse reactions to methylphenidate or amphetamines or be known to be non-responsive to methylphenidate or amphetamine treatment. Non-response is defined as methylphenidate or amphetamine use at various doses for a phase of at least four weeks at each dose with little or no clinical benefit in the past 10 years.
2. Females of child-bearing potential (FOCP) who are pregnant, planning on becoming pregnant or breast feeding.
3. Having a history of hyperthyroidism, thyrotoxicosis, advanced arteriosclerosis, severe renal insufficiency or glaucoma.
4. Having structural cardiac abnormalities, symptomatic cardiovascular disease or moderate to severe hypertension.
5. Currently, or within the past 14 days, receiving MAO inhibitors.
6. Having a primary diagnosis of bipolar disorder, as assessed at Visit 1.
7. Currently receiving any investigational drug, or have received an investigational drug in the previous month.
8. Having a history of drug or alcohol abuse or dependence.
9. Currently considered a suicide risk by the Investigator.

Minimum Eligible Age

6 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No